Meta-Flux provides an AI-driven drug-discovery platform that rapidly identifies novel disease targets, elucidates mechanisms of action, predicts toxicity, and supports clinical-trial design with predictive analytics. The platform delivers high-confidence leads and actionable insights—reducing costly trial-and-error and empowering data-driven decisions from pilot studies to full clinical programmes. Tailored to each startups' needs, Meta-Flux combines scientific expertise with scalable cloud-GPU architecture to uncover critical pathways and accelerate success across the drug-development pipeline. Recent impact includes helping Celtic Bio refine its respiratory pipeline by pinpointing first-in-class targets and streamlining pre-clinical studies. Through outcome-linked pricing, Meta-Flux aligns incentives with partners to derisk innovation and speed transformative therapies to patients.